A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

January 10, 2025

Study Completion Date

June 10, 2025

Conditions
NAFLDObesityType 2 DiabetesDyslipidemiasMetabolic Syndrome
Interventions
DRUG

Saroglitazar

4 Mg Oral Tablet

Trial Locations (19)

Unknown

RECRUITING

Gastroplus Digestive Disease Centre, Ahmedabad

RECRUITING

Mission GastroHospital, Ahmedabad

RECRUITING

Artemis Hospital, Gūrgaon

RECRUITING

Medanta- TheMedicity, Gūrgaon

RECRUITING

Malla ReddyNarayanaMultispecialtyHospital, Hyderabad

RECRUITING

Osmania GeneralHospital, Hyderabad

RECRUITING

Yashoda Hospitals, Hyderabad

RECRUITING

CARE CHL -Hospitals (Unit ofConvenient HospitalLtd., Indore

RECRUITING

S R Kalla MemorialGastro and GenralHospital, Jaipur

RECRUITING

AIIMS, Khorda

RECRUITING

Medanta Hospital, Lucknow

RECRUITING

Dayanand MedicalCollege & Hospital, Ludhiāna

RECRUITING

Neurociti Hospital, Ludhiāna

RECRUITING

TNMC & BYL NairCh. Hospital, Mumbai

RECRUITING

Shree Siddhivinayak Maternity & Nursing Home, Nashik

RECRUITING

Sir GangaramHospital, New Delhi

RECRUITING

Alchemist Hospital, Panchkula

RECRUITING

Fortis Hospital, Rupnagar

RECRUITING

BAPS Pramukh Swami Hospital, Sūrat

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY